International Invasive Lobular Breast Cancer (ILC) Symposium 2023

The 2023 International Invasive Lobular Breast Cancer (ILC) Symposium will be held on September 28-30, 2023 in Pittsburgh, PA. This year’s ILC Symposium will be held as a hybrid conference with both in-person events and live web streaming. This international breast cancer symposium will connect research scientists, clinical oncologists, trainees, fellows, and breast cancer patient advocates to discuss various topics in primary and metastatic invasive lobular breast cancer (ILC). ILC is the second most common “special subtype” of breast cancer, but our understanding of its unique biology is still emerging.

Ongoing collaborations on the unmet clinical need for people diagnosed and treated each year for ILC is critical for research. GRASP is partnering with the ILC Symposium to bring our signature program of Poster Walkthroughs which will be held virtually after the conference on Oct 5, 2023. Registration for the ILC Symposium is $25 for patient advocates.

Optional Training Sessions

All times shown are Eastern Time (US/New York)

SABCS23 GRASP Training

Join us for a training session so that you can be prepared for your upcoming event. Whether joining as a GRASP scientist, poster author, mentor, or patient advocate, these sessions will help you understand your respective role. ...
12 Dec
7:00 pm - 8:00 pm
No event found!

Virtual GRASP Sessions

*Only sign up for ONE group in each of the 3 sessions below (e.g. Group 1A & 1B are happening at the same time; Group 1A & 2A are not)

Morning Session – Thurs Oct 5, 2023

All times shown are Eastern Time (US/New York)

Group 1B: HER2-low, HER2-0, & HR+ Breast Cancer; Clinical Trials Sold Out

Poster #PO1-05-12: Pooled clinical trial data analyses comparing the biology of HER2-low vs HER2-0 breast cancer in patients with metastatic breast cancer following treatment with standard single agent chemotherapy. Poster #PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a […] ...
14 Dec
10:00 am - 11:30 am

Group 1C: BRCA+ Breast Cancer; Clinical Trials; Oncofertility; Younger Populations

Poster #PO2-11-06: Anti-Müllerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials. Poster #PO1-06-09: Phase 2 Trial with safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA1/2+, HER2-negative breast cancers Big Ten […] ...
14 Dec
10:00 am - 11:30 am

Group 1D: Brain Metastasis; Novel Targets

Poster #PS11-06: Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival. Poster #PO3-06-12: Targeting fatty acid synthase in brain metastatic triple-negative breast cancer. ...
14 Dec
10:00 am - 11:30 am
No event found!

Afternoon Session – Thurs Oct 5, 2023

All times shown are Eastern Time (US/New York)

Group 2A: Lobular Breast Cancer; Imaging Sold Out

Poster #PO2-07-09: Early stage invasive lobular breast cancer is underestimated on conventional imaging including MRI. Poster #PO4-02-12: MDA iLobular prognostic pool: A novel approach for risk stratification in invasive lobular carcinoma. ...
14 Dec
2:00 pm - 3:30 pm

Group 2B: Triple Negative Breast Cancer; Clinical Trials; Side Effects

Poster #PO2-12-12: REaCT 5G: A randomized study comparing bone pain after 5 days of filgrastim or one day of pegfilgrastim for primary febrile neutropenia prophylaxis during neo-/adjuvant chemotherapy for early breast cancer. Poster #PO1-18-07: Phase I trial of combination pembrolizumab and ruxolitinib in metastatic triple negative breast cancer. ...
14 Dec
2:00 pm - 3:30 pm

Group 2D: HER2+ Breast Cancer; Clinical Trials; Antibody-drug Conjugates Sold Out

Poster #PO1-20-06: Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 +/- pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan. Poster #PO1-04-02: ACE-Breast-03: A phase 2 study of ARX788, a novel next-generation anti-HER Antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecan. ...
14 Dec
2:00 pm - 3:30 pm

Group 2E: Brain Metastasis Screening; Liver Metastasis Sold Out

Poster #PO5-25-01: Treating liver metastases by reversing cell competition between metastatic cancer cells and hepatocytes. Poster #PO2-27-09: Clinical impact of routine MRI screening for brain metastases in patients with HER2 positive or triple negative metastatic breast cancer. ...
14 Dec
2:00 pm - 3:30 pm

Group 2H: Triple Negative Breast Cancer; Clinical Trials; Predictive Biomarkers

Poster #PO1-19-07: A phase I study accessing immunotherapy combination of balstilimab and ivermectin in patients with metastatic triple negative breast cancer Poster #PO2-15-08: Exploring essential immune genes linked to pathological complete response and survival in early-stage triple-negative breast cancer (TNBC) after chemotherapy treatment. ...
14 Dec
2:00 pm - 3:30 pm
No event found!

Evening Session – Thurs Oct 5, 2023

All times shown are Eastern Time (US/New York)

Group 3A: Metastatic Breast Cancer; Immune Microenvironment Sold Out

Poster #PO1-13-04: Distinct immune signatures discriminate between patients defined as exceptional survivors of metastatic breast cancer compared to those with rapidly progressing treatment resistant breast cancers. Poster #PO1-20-12: CD8+ tumor infiltrating lymphocytes turn a cold tumor hot in metastatic breast cancer. ...
14 Dec
6:00 pm - 7:30 pm

Group 3B: HR+ Breast Cancer; Clinical Trials; Treatment Resistance Sold Out

Poster #PO2-16-05: ESR1 mutations (ESR1mut) in HR(+)HER2(-)patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for endocrine therapy (ET) resistance in real-world practice. Poster #PO3-18-06: First-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2- advanced/metastatic breast cancer (ABC) who progressed […] ...
14 Dec
6:00 pm - 7:30 pm

Group 3D: Leptomeningeal Disease

Poster #PO5-06-01: Loss of hormone receptor expression in breast cancer is associated with increased brain tropism and accelerated progression of leptomeningeal disease. Poster #PS11-03: Comparison of next-generation sequencing (NGS) results from the cerebrospinal fluid, peripheral blood, and systemic metastatic tumor tissue of patients with metastatic breast cancer (MBC) and leptomeningeal disease (LMD). ...
14 Dec
6:00 pm - 7:30 pm
No event found!

Date

Oct 05 2023
Expired!

Time

10:00 am - 7:30 pm
Category